World TB Day is recognized each year on March 24, commemorating the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacillus that causes tuberculosis (TB). World TB Day is an opportunity to raise awareness about TB and the measures needed to tackle this devastating disease. The U.S. theme for World TB Day 2018, "Wanted: leaders for a TB-free United States. We can make history. End TB" highlights the importance of engaging and empowering public health partners, clinicians, and communities in efforts to eliminate TB.
A study reported in this issue of MMWR found that in 2017, a provisional total of 9,093 TB cases were reported in the United States (rate of 2.8 cases per 100,000 persons) (1), a decrease from the 2016 case count and rate and the lowest rate and number of TB cases on record since reporting began in 1953. However, increased diagnosis and treatment of latent TB infection is important for eliminating TB in the United States (2) .
CDC is working to eliminate TB in the United States by engaging new domestic and global partners, strengthening control of TB disease, and expanding testing and treatment of latent TB infection. Additional information about World TB Day and CDC's TB elimination activities is available online (https://www.cdc.gov/tb/worldtbday).
In 2017, a total of 9,093 new cases of tuberculosis (TB) were provisionally* reported in the United States, representing an incidence rate of 2.8 cases per 100,000 population. The case count decreased by 1.8% from 2016 to 2017, and the rate declined by 2.5% over the same period. These decreases are consistent with the slight decline in TB seen over the past several years (1) . This report summarizes provisional TB surveillance data reported to CDC's National Tuberculosis Surveillance System for 2017 and in the last decade. culture-confirmed cases in 2016, the most recent year for which complete TB drug-susceptibility data were available.
State-specific TB rates (cases per 100,000 persons) ranged from 0.3 in Montana to 8.1 in Hawaii (Table 1 ) with a median state TB rate of 1.8. As has been the case for the past decade, four states (California, Florida, New York, and Texas) reported half of the total TB cases in the United States in 2017. The annual percent change in rate in recent years has slowed from an average decline of 5.3% during 2010-2013 to an average decline of 2.0% during 2014-2017. In 2017, a total of 6,346 (69.8%) of U.S. TB cases occurred among non-U.S.-born persons, 2,698 (29.7%) cases occurred among U.S.-born persons, and 49 (0.5%) occurred among persons with no reported national origin. The TB rate among non-U.S.-born persons (14.6) was 15 times the rate among U.S.-born persons (1.0) ( Figure) . Although these rates represent decreases among both groups in 2017 compared with 2016, the rate among U.S.-born persons declined 7.0%, whereas that among non-U.S.-born persons declined 0.9%.
Among non-U.S.-born persons, the highest TB rate among all racial/ethnic groups occurred among Asians (27.0 per 100,000 persons), followed by blacks (22.0) ( Table 2 ). As in previous years, in 2017, the top five countries of birth of non-U.S.-born persons with TB were Mexico (1,204; 19 .0% of all non-U.S.-born persons with TB), Philippines (783; 12.3%), India (595; 9.4%), Vietnam (526; 8.3%), and China (400; 6.3%). Persons who received a diagnosis of TB ≥10 years after arriving in the United States accounted for 2,854 (45.0%) of all TB cases among non-U.S.-born persons. Among U.S.-born persons in 2017, a total of 1,001 (37.1%) TB cases were reported among blacks, and 797 (29.5%) among whites, representing a 55% decrease in case count for each group in the past decade. The highest TB rate among U.S.-born persons was reported among Native Hawaiians and other Pacific Islanders (6.5), followed by American Indians and Alaska Natives (3.7), blacks (2.8), Asians (2.0), Hispanics (1.5), and whites (0.4).
In 2017, 388 (4.3%) TB cases were reported among persons experiencing homelessness in the year preceding diagnosis, 148 (1.6%) among persons residing in a long-term care facility at the time of diagnosis, and 266 (3.0%) among persons confined in a correctional facility at the time of diagnosis. Although cases among U.S.-born persons accounted for <30% of total TB cases in the United States, they accounted for 61.1% among those reporting homelessness, 44.6% among those in longterm care facilities, and 39.5% among persons incarcerated at the time of diagnosis. HIV status was known for 86.3% of TB cases reported in 2017; among those cases, 5.6% had coinfection with HIV.
Drug susceptibility testing results were reported for 98.3% of culture-confirmed cases in 2016. Among all 9,256 cases reported in 2016, 97 (1.0%) were multidrug-resistant (MDR) TB, including 78 (80.4%) cases with primary MDR TB,** 18 (18.6%) with a prior history of TB, and one (1.0%) with an unknown history of previous TB diagnosis. Among the 97 MDR TB cases in 2016, 89 (91.8%) occurred among 6,355 non-U.S.-born persons, accounting for 1.4% of all TB cases among non-U.S.-born persons. One case of extensively drug-resistant † † TB was reported in a non-U.S.-born person. ** Primary multidrug-resistant tuberculosis (TB) is defined as a case of TB in a person with a Mycobacterium tuberculosis isolate with resistance to at least isoniazid and rifampin and who was not previously diagnosed with or treated for drug-susceptible TB disease. † † Defined by the World Health Organization as a case of TB in a person with a Mycobacterium tuberculosis isolate with resistance to at least isoniazid and rifampin among first-line anti-TB drugs, resistance to any fluoroquinolone (e.g., ciprofloxacin or ofloxacin), and resistance to at least one second-line injectable drug (i.e., amikacin, capreomycin, or kanamycin). Cases per 100,000 population 
Discussion
In 2017, the provisional TB case count and incidence were the lowest in the United States since national TB surveillance began in 1953 (1); however, the rate in 2017 (2.8 per 100,000) is still 28 times the U.S. elimination threshold of less than one case per million persons (4). Since 2014, the annual percentage change in rate compared with the preceding year has slowed to an average decline of 2.0%. To achieve TB elimination by 2100, a sustained annual decline of 3.9% is required. § § Previous studies have indicated that reactivation of LTBI, rather than recent transmission, is the primary driver of TB disease in the United States, accounting for >80% of all TB cases (2) . Ongoing efforts to prevent TB transmission must be sustained, and efforts to detect and treat LTBI, especially among groups at high risk, must be increased.
An epidemiologic model found that substantial (i.e., quadruple) increases in LTBI testing and treatment completion would accelerate progress toward TB elimination (4). Several accepted treatment regimens are available for LTBI (5) . Among these, CDC encourages the use of shorter, rifamycin-based regimens, such as 4 months of rifampin or 3 months of onceweekly rifapentine plus isoniazid, which have better treatment § § Sustained annual percent decline to reach TB elimination calculated as the yearly incidence reduction necessary to get from current rate to one case per million persons in 2100.
completion rates (6) and are less hepatotoxic (7, 8) than a regimen of 9 months of isoniazid. Improved treatment completion, less toxicity, and shorter treatment regimens can reduce morbidity and accelerate TB elimination in the United States. Distinct disparities exist between populations affected by TB. Highly affected and vulnerable populations include persons housed in congregate settings and persons from countries with high TB prevalences. The U.S. Preventive Services Task Force (USPSTF) recommends screening for LTBI in populations at increased risk, including persons born in countries with high TB prevalences, regardless of length of residence in the United States and age (3); this recommendation is consistent with a previously published report documenting an increasing proportion of TB diagnoses among non-U.S.-born persons living in the United States for ≥10 years (9) . In addition to USPSTF screening recommendations, CDC also recommends treatment of LTBI to reduce the number of persons developing TB disease (5) . Increased support of global TB elimination efforts would help to reduce global TB and LTBI prevalence, thereby indirectly reducing the incidence of reactivation TB in the United States among non-U.S.-born persons from higher-prevalence countries.
Spending time in congregate settings, such as homeless shelters, long-term care facilities, and correctional facilities, increases the risk for TB transmission. Most requests from state or local health departments for on-site CDC assistance arise from TB outbreaks involving congregate settings serving vulnerable populations (10) . The USPSTF recommends TB testing for persons who have lived in high-risk congregate settings, such as homeless shelters and correctional facilities (3). Control of transmission requires not only preventing disease through treatment of LTBI, but also strong infection control practices in settings with increased risk for transmission.
The findings in this report are subject to at least two limitations. First, this analysis is limited to reported provisional TB cases and case rates for 2017; final results will be available in the fall of 2018. Second, case rates are calculated using 2017 population estimates as denominators.
Summary
What is already known about this topic?
Since 1993, tuberculosis (TB) case counts and rates have declined in the United States. As the number of cases decreases overall, an increasing percentage of cases occurs among non-U.S.-born persons. Disparities also exist within racial, ethnic, and social groups among U.S.-born persons with TB.
What is added by this report?
In 2017, preliminary data indicate that 9,093 new TB cases were reported in the United States, a rate of 2.8 per 100,000 population. This is the lowest case count and rate on record, representing a decrease in case count of 1.8% from 2016 to 2017 and a 2.5% decrease in rate over the same period. The annual percent decline in rate in recent years has slowed to 2.0%. To achieve TB elimination by 2100, a sustained annual decline of 3.9% is required.
What are the implications for public health practice?
Control of active TB and a major effort to decrease latent TB infection are both necessary to reduce morbidity and achieve TB elimination in the United States. An important component of this strategy is the testing and treatment of populations most at risk for latent TB infection, persons born in countries with high TB prevalence, and persons in high-risk congregate settings.
Since 2015, TB case counts and rates in the United States have declined, in large part because of the work of local TB programs in detecting and treating persons with TB disease. Approximately 96% of persons with diagnosed TB disease in the United States complete therapy (1), thereby limiting the risk for further transmission and development of MDR TB. TB is preventable through LTBI testing and treatment and implementation of effective infection control measures; however, TB elimination goals in the United States will not be achieved without steadfast engagement among public health partners and sustained prevention and control programs. Public health priorities for TB elimination in the United States include developing comprehensive and innovative approaches to diagnosing, treating, and monitoring LTBI; continued engagement by the United States in global TB control efforts; and enhanced efforts to prevent TB transmission in the United States, particularly in congregate settings.
